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total number of patients with stable angina who have indications for ivabradine 
was 17559 people. The number of prevented cases of non-fatal myocardial infarc-
tion and unstable angina was 244 cases per year. The number of prevented cases 
of cardiovascular death was 95 cases per year. The number of prevented cases of 
surgical revascularization was 260 cases per year. ConClusions: The analysis 
allowed to identify Belarusian patients in need of ivabradine use by estimating 
the size of the target group of patients with stable angina and elevated heart 
rate for whom antianginal therapy is inadequate or impossible and who need an 
ivabradine prescription and potentially could make the most effective reaction 
to the therapy.
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EVidEnCE ThrEsholds in ThE AbsEnCE of EffECTiVE AlTErnATiVEs: ThE 
CAsE of inTErmiTTEnT ComPrEssion in CriTiCAl limb isChEmiA
Moran P., Teljeur C., Harrington P., Ryan M.
Health Information and Quality Authority, Dublin, Ireland
objeCtives: Intermittent pneumatic compression (IPC) is proposed as an adjunct 
to medical care for people with critical limb ischemia (CLI) who are unsuitable for 
revascularisation. Given the lack of treatment options for these patients, a safe 
therapy that can be shown to provide even a modest clinical improvement may 
make a significant contribution to the management of this condition. This research 
aims to synthesise and critically appraise the evidence supporting the use of this 
technology in this cohort. Methods: A systematic review of the clinical effective-
ness of IPC in non-reconstructable CLI was performed. Medline, Embase and trial 
registries were searched for randomised controlled trials (RCTs), non-randomised 
controlled trials (nRCTs) and controlled before-and-after (CBA) studies compar-
ing IPC plus medical care to medical care only. Results: No RCTs or nRCTs were 
identified. Two CBA studies, both with a high risk of bias, found that IPC was asso-
ciated with improved limb salvage and wound healing (OR 7, 95% CI 1.82 to 26.89, 
p< 0.05 for both outcomes) as well as improved quality of life scores in bodily pain 
(mean difference [MD] 32.7, 95% CI 29.4 to 36.0, p< 0.05) and physical functioning 
(MD 18.8, 95% CI 14.1 to 23.6, p< 0.05). Improvements were also reported for initial 
and absolute claudication distances (MD 26.9m, 95% CI 21.7 to 32.1, p< 0.05; MD 
52.9m, 95% CI 42.2 to 63.6, p< 0.05, respectively). No serious adverse events were 
reported. ConClusions: Despite some promising results there is a lack of high-
quality evidence demonstrating the effectiveness of IPC in addition to medical 
management in non-reconstructable CLI. Where findings are equivocal a question 
arises as to the minimum level of evidence required to support the introduction of 
a technology when no effective alternatives exist. Competing interpretations of the 
balance of risks and benefits between different stakeholders in the decision-making 
process in these circumstances are discussed.
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objeCtives: To evaluate excess use of coronary angiography prior to coronary 
artery bypass graft (CABG) surgery and its association with mortality, health care 
costs and hospital quality in Turkey. Methods: MEDULA, a nationwide integrated 
system shared between general health insurance and health care providers in 
Turkey was used to analyze coronary angiography utilization. Patients age 18–99 
years who underwent CABG surgery between April 1, 2009 and October 1, 2010 were 
identified and assigned to “standard-therapy” or “excess-use” groups based on 
whether they had one or more coronary angiography, respectively, within 3 months 
of the first CABG diagnosis date (index date) during the identification period. 
Survival rates and annual health care costs of patients in the coronary angiog-
raphy standard-therapy and excess-use groups were compared using propensity 
score matching. The empirical Bayes approach was used to combine mortality 
and hospital volume for quality index. Chi-squared tests were used to assess the 
relationship between hospital quality and excess use of coronary angiography 
excess use. Results: From a total of 20,126 identified patients, 7.27% underwent 
excessive coronary angiography procedures, at average annual costs that were 
9.7% higher than patients with a single angiography (p< 0.01). Operational mortal-
ity associated with excessive use was significantly higher as well (7.4% vs. 5.4%, 
p< 0.02). Use of coronary angiography across cities and hospitals varied. Patients 
who underwent cardiac surgery in high-quality hospitals were less likely to have 
excessive angiography use than those in low-quality hospitals (7.0% vs. 9.5%, 
p< 0.01). ConClusions: In Turkey, excess use of coronary angiography prior to 
CABG surgery is associated with higher operational mortality, higher expenditures 
and lower hospital quality.
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objeCtives: To examined anticoagulant use and associated factors in hospitalized 
patients with acute venous thromboembolism (VTE) in the US clinical practice set-
ting. Methods: Adult VTE patients were selected from the linked MarketScan and 
Hospital Drug database in an inpatient setting between 07/01/2006-12/31/2011. The 
first hospitalization with a diagnosis of VTE was designated index hospitalization 
(IH). Patients were required to have at least 6 months continuous enrollment and 
dabigatran and rivaroxaban appear to have better safety and efficacy profiles when 
compared with warfarin. Apixaban and dabigatran 110mg consistently demon-
strated reduced risk of bleeding when compared with rivaroxaban and dabigatran 
150mg. Dabigatran150mg demonstrated increased efficacy on multiple endpoints 
when compared with rivaroxaban, while discontinuation rates were increased. 
Head-to-head studies would help clarify any differences among these medicines 
for efficacy and bleeding.
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mETA-AnAlysis of sAfETy of dAbigATrAn And wArfArin for TrEATmEnT 
of ATriAl fibrillATion
Aggarwal S., Segal J.
Novel Health Strategies, Bethesda, MD, USA
objeCtives: Atrial fibrillation (AF) is an irregular and often rapid heart rate that 
commonly causes poor blood flow to the body. Dabigatran and Warfarin have 
shown safety and efficacy for treatment of AF. The objective of this study was 
to conduct meta-analysis and present evidence for safety of Dabigatran versus 
Warfarin for treatment of AF. Methods: For this meta-analysis we included 
randomized controlled trials (RCTs) evaluating Dabigatran for the treatment of 
AF. We included studies that were: (1) a RCT in humans; (2) an investigation of 
patients with nonvalvular atrial fibrillation; (3) an evaluation of dabigatran com-
pared with warfarin or each other; and (4) a report of results of stroke or systemic 
emboli and major bleeding. A systematic literature search for dabigatran trials 
was undertaken for the databases Pubmed, Embase, Biosis, Google Scholar, and 
Cochrane. Data was collected for the study size, interventions, year and total 
bleeding events. For meta-analysis, random effects and fixed effects models were 
used to obtain cumulative statistics. Results: Two RCTs with a total of 12,268 
patients were identified. The pooled event rate for Dabigatran for total bleeding 
events was 31.9% (95% CI 31%-33%). The pooled response rate for Warfarin for 
total bleeding events was 35.1% (95% CI 34%-37%). The cumulative relative risk 
for total bleeding events with Dabigatran versus Warfarin was 0.91 (95% CI 0.89-
0.93) ConClusions: Meta-analysis shows Dabigatran has a slightly lower rate 
of total bleeding events compared to Warfarin.
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EffECT of iVAbrAdinE on ThAi ChroniC sTAblE AnginA PECToris 
PATiEnTs
Rojkajornnaphalai S.
Chest Hospital, Nonthaburi, Thailand
objeCtives: To evaluate efficacy/safety of ivabradine in chronic stable angina 
pectoris(CSAP) Thai patients. Methods: Ivabradine 5-7.5 mg bid was prescribed 
to CSAP patients. Hemodynamic parameters including systolic/diastolic blood 
pressure(SBP/DBP) in mmHg and heart rate(HR) in beats per minute(bpm) were 
recorded at entry and after 1,4 months follow-up. A standardized digital device 
was used to monitor BP and HR. Acceptability was evaluated in patient inter-
views. Results: A total of 256 patients, men/women ratio of 1.04, mean(SD) age 
67.1(12.4) years, 149(58%) were > 65 years old, 64(25%) and 76(29.7%) of patients 
had previous intervention and heart failure(HF). 127(50%)&51(20%) received beta-
blockers&nitrate as initial medication. Patients’ assessment was made using 
Canadian Cardiology Society angina pectoris classification(CCS). At entry, 34.9%, 
52.2% and 10.8% of patients were found with CCS grades 3, 2 and 1. Among 76 HF 
patients, 35.8%, 58.2% and 6.0% were found with stage 3, 2 and 1 of NYHA classifica-
tion. In overall population, mean(SD) baseline HR was 86.9(11.2) bpm and SBP/DBP 
137.8(24.6)/81.7(15.9) mmHg. After 4 months, mean(SD), HR significantly reduced to 
69.96(7.13)bpm (p< 0.001) and SBP/DBP lowered to 126.5(12.9)/73.9(8.9) mmHg, while 
mean arterial pressure(MAP)was optimally maintained at 100.4(17.6) mmHg. The 
highly significant drop in mean difference(SE) HR of 16.9(0.7) was observed with 
95% CI between 15.5-18.3 bpm. No significant mean difference(SE),[95% CI] SBP 
drop, between patients with/without HF, and with/without previous intervention 
of 7.32(1.17),[4.99-9.64] and 8.15(2.07),[4.02-12.2764], or 8.14(1.27),[5.61-10.67] and 
7.46(0.89),[5.69-9.22] (p= 0.502, p= 0.691) respectively. Improvement for CCS 3 and 
CCS 2 angina class, reduced to 1.9% and 36.1% whereas the NYHA classification 
for stage 3&2 reduced to 3.2%&56.4%(p< 0.001). Common AE reported were palpita-
tion(2.5%) and nausea(1%). ConClusions: Ivabradine is a well-tolerated heart rate 
reducing agent, effective for both chronic stable angina pectoris and heart failure. 
It effectively reduces elevated heart rate without affecting other hemodynamic 
parameters. In this Thai setting, ivabradine significantly improves CCS and NYHA 
classifications with minimal side effects being reported.
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EVAlUATion of ThE PoTEnTiAl EffiCACy of iVAbrAdinE in hEAlTh CArE 
of ThE rEPUbliC of bElArUs
Kozhanova I.1, Romanova I.1, Gavrilenko L.1, Sachek M.2
1Belarusian State Medical University, Minsk, Belarus, 2The Belarusian Center for Medical 
Technologies, Computer Systems, Administration and Management of Health, Minsk, Belarus
objeCtives: To determine the potential population of patients with stable angina 
pectoris in Belarus who need prescription of ivabradine and setting the amount of 
the effect of the drug in this group of patients. Methods: In the research phar-
macoeconomic Markov model of ivabradine application in patients with stable 
angina, national surveillance data, analysis of literature have been used. Patients 
with stable angina after revascularization, patients with contraindications to 
beta-blocker use, not applying the dihydropyridines and having a contraindica-
tion to ivabradine use have been used to determine the target population. The 
number of prevented or postponed events – PPE - (nonfatal myocardial infarction 
and unstable angina, cardiovascular death, the number of surgical revasculariza-
tion) has been calculated. For the potential efficacy of ivabradine use in patients 
with stable angina and heart rate ≥ 70 bpm calculating the data about efficacy in 
accordance with the results of the Beautiful study were used Results: The total 
number of patients with stable angina pectoris in Belarus in 2011 was 242943. The 
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objeCtives: This study investigated the outcomes and management associated 
with stroke prevention treatments in patients with non-valvular atrial fibrilla-
tion (NVAF) in Europe. The primary objective of this analysis was to assess the 
management of patients treated with vitamin K antagonists (VKA). Methods: 
We conducted an observational retrospective cohort study of patients with NVAF 
in the Longitudinal Patient Database (CEGEDIM) in France, Italy, the UK, Spain and 
Germany. The analysis included patients > = 18 years old with recorded AF diag-
nosis, treated with VKA, and without rheumatic valvular disease or prosthetic 
valves prior to the index date (date of 1stvisit during inclusion period – May 2010 
- April 2012 - , or date for first AF diagnosis, if this falls during this period. Only 
patients with > = 1 year of data were included to ensure adequate data avail-
ability. Using recorded INR measures, we estimated the average time within 
therapeutic range (TTR), INR between 2 and 3 for patients eligible to apply the 
Rosendaal Method. Results: In France 1,110 patients were assessed, in Germany 
1,208, in Italy 1,230, & the UK 2,702. Insufficient data were retrieved in Spain 
(n= 12). INR was measured 9.6 times/year in France, 9.5 times/year in Germany, 
9.8times/year in Italy, and 13.1 times/year in the UK. In France, 48% of the patients 
had TTR > = 70% of their time; in Germany, 44%; in Italy, 46%, and in the UK, 
65%. ConClusions: Treatment outcomes with VKAs, in particular stroke and 
bleeding, depend on maintaining patients’ INR values within recommended 
range. The results show that the majority of patients in France, Germany and 
Italy, & 1/3 of patients in UK did not achieve recommended TTR and therefore 
were at increased risk of stroke or major bleeding. Further research is needed 
to demonstrate the correlation between these estimates and stroke and major 
bleeding rates within countries.
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PhArmACoEPidEmiologiCAl sTUdy of hmg CoA rEdUCTAsE inhibiTor 
PrEsCribing: imPACT of gEnEriC PrEsCribing on CosT
Truter I.
Nelson Mandela Metropolitan University, Port Elizabeth, South Africa
objeCtives: To investigate the prescribing of hypolipidaemic agents with specific 
emphasis on the effect of generic prescribing on HMG-CoA reductase inhibitor (statin) 
costs. Methods: A retrospective, cross-sectional pharmacoepidemiological study 
was conducted on 2011 medical insurance claims data in South Africa. Results: A 
total of 4805 patients (56.88% males) were prescribed 38373 hypolipidaemic agents. 
The average age of patients was 56.07 (SD= 13.32) years. Statins accounted for 93.85% 
of all prescriptions and 83.44% of cost, followed by fibrates (3.61% of prescribing fre-
quency and 7.72% of cost). Simvastatin was the most frequently prescribed statin 
(accounting for 62.59% of all prescriptions), followed by atorvastatin (17.04%) and 
rosuvastatin (11.68%). Simvastatin was also the active ingredient with the lowest aver-
age cost per product of R46.43. Simvastatin was prescribed under 16, atorvastatin six 
and pravastatin four different trade names. Fluvastatin, lovastatin and rosuvastatin 
only had one trade name under which they were prescribed. Only one cholesterol 
absorption inhibitor drug was prescribed (ezetimibe) accounting for 1.64% of prescrip-
tions. This product had the highest average cost per prescription of R416.37. Other 
hypolipidaemic agents prescribed accounted for only 0.89% and consisted of the com-
bination of ezetimibe and simvastatin, and cholestyramine. The fibrates constituted 
3.61% of prescribing, with most prescriptions for bezafibrate. Dosages for the statins 
were investigated and it was found that the average Prescribed Daily Doses (PDDs) 
were generally lower or in agreement with the Defined Daily Doses (DDDs). The aver-
age PDD of simvastatin was 23.70 (DDD= 30 mg), pravastatin 25.35 mg (DDD= 30 mg), 
lovastatin 26.31 mg (DDD= 45 mg), atorvastatin 20.91 (DDD= 20 mg) and fluvastatin 
57.29 mg (DDD= 60 mg). ConClusions: There are a variety of generic equivalents 
available for the statins on the South African market. It was clear that products with 
more generic equivalents had a lower average cost per prescription compared to the 
innovator products.
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UsE of CAlCiUm ChAnnEl bloCkErs in sErbiA in ThE PEriod from 2007 To 
2011 yEAr
Milijasevic D., Milijasevic B., Tomic N., Sabo A., Raskovic A., Horvat O.
Faculty of Medicine, University of Novi Sad, Serbia, Novi Sad, Serbia and Montenegro
objeCtives: Calcium channel blockers are drugs of first choice in the treatment 
of hypertension. The aim of this study was to analyze the consumption of calcium 
channel blockers in Serbia in the period from 2007 to 2011 year. Methods: The data 
about the use of drugs were taken from the Agency for Drugs and Medical Devices 
of the Serbia. Results: The most frequently used drug from this group with mainly 
vascular effects was amlodipine. During this observed five years the consumption 
of amlodipine is in steadily increased. In 2007. it was 21.25DDD/1000 inh/day, at the 
end of 2011. year the consumption was 72.97DDD/1000 inh/day. On the second place 
in drug consumption in the same group of drugs was nifedipine. Contrary to amlodi-
pine, nifedipine recorded a decline in consumption. From the calcium channel 
blockers with direct cardiac effects the most frequently used drugs were verapamil 
and diltiazem. The consumption of verapamil in the observed years was uneven. At 
the and of 2011. consumption of this drug was reduced by 50%. The consumption 
of diltiazem in observed five years is in constantly decreasing. ConClusions: In 
Serbia, in the observed period the consumption of calcium channel blockers been 
uneven. In 2010 and 2011 the consumption of calcium channel blockers marks a 
positive trend. This research was supported by Provincial Secretariat for Science 
and Technological Development, Autonomous Province of Vojvodina project No 
114-451-2458/2011 and by Ministry of Science, Republic of Serbia, project no 41012.
have no VTE diagnosis in the 6 months prior to IH. Parenteral and oral anticoagu-
lants used during IH were identified. Multivariate logistic regression was used to 
examine factors associated with anticoagulant use. Results: A total of 957 VTE 
patients were eligible for the study. Mean age was 62.8 years, and 45.1% were male. 
Mean length of stay was 8.7 days. During index hospitalization, 45.4% patients 
were treated with parenteral anticoagulants (PA) and warfarin, 24.6% with warfa-
rin only, and 13.6% with PA only. Among patients treated with PA, low molecular 
weight heparin accounted for 93.4%. Chemotherapy (OR= 2.24), respiratory disease 
(OR= 1.44), and pulmonary embolism (PE) vs deep vein thrombosis (DVT) (OR= 1.42) 
were significantly associated with PA use, while prior stroke (OR= 0.43) and renal 
disease (OR= 0.58) were associated with less likelihood of PA use. DVT plus PE 
vs DVT (OR= 3.87), obesity (OR= 2.57), chemotherapy (OR= 2.23), and PE vs DVT 
(OR= 2.19) were significantly associated with warfarin use, while bleeding history 
(OR= 0.41), diabetes (OR= 0.64), and heart disease (OR= 0.67) were associated with 
less likelihood of warfarin use. ConClusions: Less than half of VTE patients dur-
ing hospitalization were prescribed PA and warfarin, 25% warfarin only, and 14% 
PA only. Clinical factors including VTE type, stroke and bleeding history, comorbid 
respiratory disease, diabetes, heart disease, obesity, and chemotherapy were asso-
ciated with anticoagulant use. Further research needs to examine characteristics 
and health outcomes of patients who did not receive parenteral anticoagulants 
during hospitalization.
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objeCtives: The REACT AF study investigated the outcomes and management 
associated with stroke prevention treatments in patients with non-valvular atrial 
fibrillation (NVAF) in Europe. This analysis assessed 1) the use of oral anticoagulation 
drugs (OACs) and 2) whether current practice is consistent with the 2012 European 
Society of Cardiology (ESC) recommendations. Methods: We conducted an obser-
vational retrospective cohort study of patients with NVAF in the Longitudinal Patient 
Database (CEGEDIM) in France, Italy, UK, Spain and Germany. The analysis included 
patients > = 18 years old, with AF diagnosis, and without rheumatic valvular disease 
or prosthetic valves. Patients had to be in the database for ≥ 1 year before date of 1st 
visit (index date) during the inclusion period (May 2010-April 2012). We calculated 
patients’ CHA2DS2-VASc score at index date for untreated patients and at the time of 
the current OAC initiation for treated patients. We evaluated patients’ requirement 
for stroke prevention therapy based on the 2012 ESC recommendations and calcu-
lated the percentage of patients for whom treatment initiation and OAC use were 
consistent with recommendations. Results: In France 53% of the OAC patients 
(total= 16,329) were treated consistently with the 2012 ESC recommendations (treat-
ment requirement and choice of OAC); 46% in Germany (total= 13,468), 58% in Spain 
(total= 12,357); 39% in Italy (total= 22,447); and 36% in the UK (total= 19,956). The per-
centage of patients (CHA2DS2-Vasc> 1, if not alone due to female gender) not receiv-
ing the required treatment (either not treated or treated with a non-recommended 
OAC) was 36% in France; 48% in Germany; 34% in Spain; 52% in Italy; and 48% in 
the UK. ConClusions: The study findings indicate there is a discrepancy between 
current practice regarding OAC prescribing and the 2012 ESC recommendations. 
Special attention must be given to time of treatment initiation and choice of OAC 
to correctly follow ESC recommendations.
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objeCtives: This study investigated the outcomes and management associated 
with stroke prevention treatments in patients with non-valvular atrial fibrillation 
(NVAF) in Europe. This analysis estimated persistence and adherence to treatment 
with VKA. Methods: We conducted an observational retrospective cohort study 
of patients with NVAF in the Longitudinal Patient Database (CEGEDIM) in France, Italy, 
the UK, Spain and Germany. The analysis included patients > = 18 years old, with 
AF diagnosis, treated with VKA and without rheumatic valvular disease or pros-
thetic valves. Patients had to be in the database for > = 1 year before date of 1stvisit 
during inclusion period (May 2010/April 2012). We estimated persistence (time to 
VKA discontinuation) as the time from first prescription to last prescription before 
discontinuation, defining discontinuation as switch or absence of renewal within 
3 months, using the Kaplan-Meier method. We measured adherence to treatment 
by the Medication Possession Ratio (MPR) during the inclusion period. Results: 
Median time to treatment discontinuation was 0.78 year in Germany (n= 6,386), 1.00 
year in Italy (n= 8,774), 1.34 years in France (n= 9,184), 1.99 years in Spain (n= 7,526), 
and 1.92 years in the UK (n= 7,731). Persistence at 5 years was 12% in Germany, 20% 
in Italy, 24% in France, 26% in Spain, and 25% in the UK. Concerning adherence the 
mean MPR was 0.54 in Spain, 0.56 in Italy, 0.57 in France, and 0.59 in Germany. There 
was insufficient data to estimate adherence in the UK. ConClusions: MPR > = 0.80 
is used to define good adherence. The results show adherence to treatment with 
VKA is low in the countries studied. Results were consistent across countries, which 
suggest that low adherence is not country specific. Low adherence to treatment with 
VKA can affect the maintenance of patients within recommended range of INR, and 
therefore may increase the risk of stroke.
